Shimadzu recently developed Amyloid Mass Spectrometry (MS) Service — a new simple, low-cost blood analysis for early screening of amyloid-positive subjects. This method enables early and accurate prediction of amyloid deposition in the brain with an easy-to-acquire blood sample.
Unlike conventional methods, Shimadzu’s new analysis is minimally invasive, cost-effective and suitable for large-scale deployment.
For Research Use Only. Not for use in diagnostic procedures.
Amyloid MS Service is for drug discovery and development only.
Shimadzu has built an efficient process for analyzing samples:
Amyloid™ MS Service Offers New Research Opportunities for Alzheimer's Disease
One of the earliest signs of Alzheimer’s is amyloid-beta deposition in the brain. Shimadzu’s Amyloid MS Service enables early and accurate detection of amyloid deposition in the brain with an easy-to-acquire sample. Unlike conventional methods, Shimadzu’s Amyloid MS Service is cost-effective, minimally invasive and suitable for large-scale deployment.
